Empagliflozin shows efficacy as stand-alone diabetes treatment

10/4/2013 | Medscape (free registration)

Previously untreated type 2 diabetes patients who either took empagliflozin or sitagliptin showed greater improvements in A1C compared with a placebo group, according to a study in The Lancet Diabetes & Endocrinology. Patients in the empagliflozin arm also showed better fasting plasma glucose and greater reductions in weight, waist size and systolic blood pressure compared with the sitagliptin group, suggesting the drug is effective as monotherapy.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA